Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours

NCT06581432 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06581432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06581432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Recruiting
Start date
October 11, 2024
Completion date
December 29, 2028
Enrollment
588 (estimated)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours